Everolimus News and Research

RSS

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.

26 Sep 2015

Drug combination delivers effective punch against one form of pancreatic cancer

One form of pancreatic cancer has a new enemy: a two-drug combination discovered by UF Health researchers that inhibits tumors and kills cancer cells in mouse models.

22 Sep 2015

Bioresorbable vascular scaffold shows similar safety, efficacy results compared to metal stent

A drug-eluting coronary stent, or "scaffold" made from bioresorbable material, showed similar efficacy and safety results compared to a metal stent in patients undergoing percutaneous coronary intervention (PCI), according to results of the ABSORB Japan study.

1 Sep 2015

PRESTIGE study suggests novel target to prevent stent thrombosis

Recruitment of leukocytes is a hallmark of stent thrombosis, according to results from the PRESTIGE study presented today at ESC Congress and published in European Heart Journal. The findings suggest that immune cell mediated thrombotic processes may be a realistic target for novel therapies to prevent stent thrombosis.

1 Sep 2015

STEMI study: Absorbable stents perform similarly to metallic stents

A drug-eluting coronary stent made of absorbable material performed similarly to the gold-standard metal one in a non-inferiority trial among patients with the more serious type of heart attack known as ST-segment elevation myocardial infarction (STEMI), according to results of the ABSORB STEMI TROFI II trial.

1 Sep 2015

Abbott reports positive results of ABSORB Japan study comparing efficacy of fully dissolving heart stent to XIENCE

Abbott (NYSE: ABT) announced today positive one-year clinical results from ABSORB Japan, a multi-center, randomized trial comparing the safety and effectiveness of Abbott's fully dissolving Absorb™ heart stent to XIENCE ®, Abbott's market-leading, permanent drug eluting stent.

1 Sep 2015

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel-based dual antiplatelet therapy is associated with increased major bleeding after stent implantation for high-risk patients with stable coronary artery disease, according to a secondary analysis of the BASKET-PROVE II trial presented at ESC Congress for the first time today.

1 Sep 2015

ESC Congress to highlight results from global trials in six press conferences

Members of the press will be the first to hear the highly anticipated results from global trials in six press conferences devoted to hot lines research.

13 Aug 2015

Boston Scientific commences new study to evaluate fully resorbable drug-eluting scaffold system

Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully Absorbable Scaffold Feasibility Study (FAST) is a prospective, single arm study designed to assess the safety and performance of this next generation scaffold for the treatment of atherosclerotic coronary lesions.

21 Jul 2015

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone.

1 Jun 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.

1 Jun 2015

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Researchers from the Abramson Cancer Center of the University of Pennsylvania and Penn's Perelman School of Medicine will present results from several clinical trials and other key studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 through June 2.

30 May 2015

Study compares effectiveness of treatments for metastatic non-clear cell kidney cancers

A head-to-head comparison of two biologic therapies used to treat a subset of patients with advanced kidney cancers provides much-needed clarity on the preferred treatment for the first line of attack.

15 May 2015

Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced that it will present a poster with new data on the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the 7th Asian Oncology Summit being held from April 10-12, 2015 in Shanghai, China.

10 Apr 2015

Alternating sunitinib, everolimus not supported in advanced RCC

Australian researchers report that an alternating regimen of sunitinib and everolimus, although feasible and low-risk in patients with advanced renal cell carcinoma, failed to meet the prespecified criteria for use or continued development.

25 Mar 2015

Patients with multiple narrowed arteries have better outcomes with CABG than with PCI

Despite the advent of a new generation of stents, patients with multiple narrowed arteries in the heart who received coronary artery bypass grafting fared better than those whose arteries were opened with balloon angioplasty and stents in a study presented at the American College of Cardiology's 64th Annual Scientific Session.

17 Mar 2015

Study compares latest drug-coated stents with traditional bypass surgery

Newer drug-coated stents that keep arteries open have similar long-term rates of death compared with traditional bypass surgery for patients with more than one diseased coronary artery.

17 Mar 2015

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).

25 Feb 2015

Drugs delay disease progression for women with hormone-receptor-positive metastatic breast cancer

A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center phase II trial. The findings of the randomized study (S6-03) were presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 6-9, by Kerin Adelson, M.D., assistant professor of medical oncology at Yale Cancer Center and chief quality officer at Smilow Cancer Hospital at Yale-New Haven.

11 Dec 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis will highlight more than 250 abstracts demonstrating advances in blood and breast cancer research at the upcoming American Society of Hematology (ASH) annual meeting December 6-9, and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 9-13.

2 Dec 2014

Everolimus News and Research

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

Drug combination delivers effective punch against one form of pancreatic cancer

Bioresorbable vascular scaffold shows similar safety, efficacy results compared to metal stent

PRESTIGE study suggests novel target to prevent stent thrombosis

STEMI study: Absorbable stents perform similarly to metallic stents

Abbott reports positive results of ABSORB Japan study comparing efficacy of fully dissolving heart stent to XIENCE

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

ESC Congress to highlight results from global trials in six press conferences

Boston Scientific commences new study to evaluate fully resorbable drug-eluting scaffold system

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Study compares effectiveness of treatments for metastatic non-clear cell kidney cancers

Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Alternating sunitinib, everolimus not supported in advanced RCC

Patients with multiple narrowed arteries have better outcomes with CABG than with PCI

Study compares latest drug-coated stents with traditional bypass surgery

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Drugs delay disease progression for women with hormone-receptor-positive metastatic breast cancer

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News